Global Human African Trypanosomiasis Sleeping Sickness Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 92.75 Million |
 Market Size (Forecast Year) |
USD 150.30 Million |
 CAGR |
% |
| Major Markets Players |
全球人类非洲锥虫病（昏睡病）市场，按类型（布氏冈比亚锥虫 (TbG)、布氏罗德西亚锥虫 (TbR)）、症状（第 1 阶段：发烧、头痛、瘙痒、关节痛，第 2 阶段：睡眠困难、意识模糊、协调性差）、治疗（喷他脒、苏拉明、美拉胂醇、依氟鸟氨酸和与依氟鸟氨酸联合使用的硝呋噻氧）、诊断方法（血涂片、腰椎穿刺）、国家（美国、加拿大、墨西哥、巴西、阿根廷、秘鲁、南美洲其他地区、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、匈牙利、立陶宛、奥地利、爱尔兰、挪威、波兰、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、越南、亚太其他地区、沙特阿拉伯、阿联酋、埃及、以色列、科威特、南非、中东和非洲其他地区）行业趋势和预测到 2028 年。
市场分析与洞察：全球非洲人类锥虫病（昏睡病）市场
预计全球人类非洲锥虫病（昏睡病）市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在上述研究预测期内，市场复合年增长率为 7.0%。
非洲人类锥虫病 (HAT)，通常称为昏睡病，是一种影响撒哈拉以南非洲人类的媒介传播疾病。它是由寄生原生动物布氏锥虫引起的。它有两个可以感染人类的亚种，分别是冈比亚锥虫和罗德西亚锥虫。这两种寄生虫通常通过受感染的采采蝇 (舌蝇属) 传播给人类，采采蝇是一种栖息在受感染地区的大型吸血蝇。寄生虫首先在血液、淋巴和外周器官中发育（第 1 阶段），然后进一步扩散到中枢神经系统（第 2 阶段），在那里它们会引起严重的神经系统疾病。这些感染引起的疾病如果不治疗通常是致命的。
据了解，HAT 发生在撒哈拉以南非洲 36 个国家的农村地区，采采蝇是这些地区的特有物种。T. b. gambiense 分布在中非、西非和东非部分地区，而 T. b. rhodesiense 分布在南非和东非。在非洲特有地区，估计有 10 000-30 000 例病例，其中 95% 以上是由 T. b. gambiense HAT 引起的。在本文介绍的病例中，约 30% 的病例是由 T. b. gambiense HAT 引起的，70% 的病例是由 T. b. rhodesiense HAT 引起的。
The major problem in non-endemic regions is an initial misdiagnosis, mostly of T. b. gambiense HAT. The chronic nature, characterized by non-specific clinical signs and symptoms, and low parasitemia, may result in the disease remaining undiagnosed and unrecognized for years. Another problem was complicating the management of patients is the availability of drugs to treat HAT.
General recommendations to prevent tsetse-fly">tsetse fly bites include wearing light-colored clothing that fully covers the arms and legs, as well as the use of personal insecticides. The most effective means for preventing /trypanosomiasis">trypanosomiasis, both in travelers and in those living in endemic areas, is the control and reduction of vectors and reservoirs.
The governments of disease-endemic countries are committed to controlling the disease and several initiatives to coordinate efforts have begun. These include the Pan-African Tsetse and Trypanosomiasis Eradication Campaign and the Programme against African Trypanosomiasis.
The development of vaccines aimed to reduce T.b. transmission through immunization against insect parasite stages which express an invariant glycoprotein coat that is, blocking the parasitemia onset in the host, as the successful anti-tick vaccine. Several antigens have been already proposed as candidates for such experimental vaccination schemes and are being tested.
Only four drugs are approved to treat HAT. However, eflornithine and pentamidine are ineffective against sleeping sickness caused by T.b. rhodesiense. Treatment with melarsoprol, the only generally effective first-line drug, required lengthy parenteral administration and can result in up to 10% mortality. Additionally, the toxicity and the upsurge in the number of patients failing to respond to melarsoprol because of drug resistance reflect the need for the discovery of new chemotherapeutic agents against HAT. To this effect, the insufficiency of current therapies for the treatment and management of trypanosomiasis, combined with both a lack of trust in conventional medical treatment and an inability of the economy to absorb the cost of pharmaceuticals, have created a growing public interest in alternative natural drugs from botanicals.
This human African trypanosomiasis (sleeping sickness) market provides details of market share, new developments and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the human African trypanosomiasis (sleeping sickness) market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Human African Trypanosomiasis (Sleeping Sickness) Market Scope and Market Size
The global human African trypanosomiasis (sleeping sickness) market is segmented based on type, symptoms, treatment and diagnostic method. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with the valuable market overview and market insights to help them in making strategic decisions for the identification of core market applications.
- Based on type, the human African trypanosomiasis (sleeping sickness) market is segmented into trypanosoma brucei gambiense (TbG) and trypanosoma brucei rhodesiense (TbR).
- Based on symptoms, the human African trypanosomiasis (sleeping sickness) market is segmented into stage 1: fevers, headaches, itchiness, joint pains and stage 2: trouble sleeping, confusion and poor coordination.
- Based on treatment, the human African trypanosomiasis (sleeping sickness) market is segmented into pentamidine, suramin, melarsoprol, eflornithine and nifurtimox when used in combination with eflornithine.
- Based on diagnostic method, the human African trypanosomiasis (sleeping sickness) market is segmented into blood smear and lumbar puncture.
Global Human African Trypanosomiasis (Sleeping Sickness) Market Country Level Analysis
The human African trypanosomiasis (sleeping sickness) market is analyzed and market size insights and trends are provided by type, symptoms, treatment and diagnostic method as referenced above.
North America dominates the human African trypanosomiasis (sleeping sickness) market due to changing lifestyle and also due to rising healthcare expenditure as well as increasing availability of funds for research, huge patient population, well-developed healthcare sector coupled with increasing government support for research & development in the region.
The countries covered human African trypanosomiasis (sleeping sickness) market reports are the U.S., Canada, Mexico, Brazil, Argentina, Peru, the Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of the Middle East and Africa.
报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、销售渠道的影响。
竞争格局和非洲人类锥虫病（昏睡病）市场份额分析
非洲人类锥虫病（昏睡病） 市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对非洲人类锥虫病（昏睡病）市场的关注有关。
非洲人类锥虫病（昏睡病）市场的主要参与者包括 Sara Healthcare Pvt. Ltd、拜耳制药公司、台湾神农制药有限公司、Micro Orgo Chem、Rusan Pharma Ltd、Sanofi-Aventis groupe 等国内和全球参与者。市场份额数据分别针对全球、北美、欧洲、亚太地区 (APAC)、中东和非洲 (MEA) 和南美提供。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
